Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript February 27, 2024 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.31, expectations were $-1.37. Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
Tarsus Pharmaceuticals, Inc. announced topline results from the Ersa Phase 2a clinical trial evaluating TP-03 administered twice daily or three times a day for 12 weeks for the treatment of Meibomian.
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) Tarsus Pharmaceuticals, Inc. TARS, whose mission is to focus on unmet needs and apply proven science and new…